NanoViricides, Inc. (NYSE American: NNVC) announced a securities purchase agreement with a single institutional investor for a registered direct offering expected to generate approximately $2 million in gross proceeds. The offering involves the sale of 1,333,334 common shares, or pre-funded warrants in lieu thereof, along with accompanying warrants to purchase an equal number of common shares. The accompanying warrants carry an exercise price of $1.75 per share and a three-year term, with closing expected on or about May 18, 2026, subject to customary conditions.
This capital raise is significant for NanoViricides as it continues to develop its lead drug candidate, NV-387, a broad-spectrum antiviral based on host-mimetic nanomedicine technology. NV-387 has been granted Orphan Drug Designation (ODD) by the U.S. FDA Office of Orphan Products Development, which could provide seven years of market exclusivity, tax credits for clinical trial costs, and fee exemptions upon approval. The drug is designed to be effective against a range of respiratory viral illnesses, including Influenza, RSV, Coronaviruses, and has shown efficacy in lethal animal infection models of Monkeypox, Smallpox, and Measles.
The funding from this offering will likely support ongoing clinical trials and development efforts for NV-387, which the company believes could become a first-line treatment for patients presenting with respiratory viral illnesses. The ability to secure investment from an institutional investor underscores confidence in NanoViricides' technology and pipeline.
For investors, this offering provides insight into the company's financial strategy and the potential market impact of NV-387. If approved, NV-387 could address a significant unmet need for broad-spectrum antivirals, particularly in the context of emerging viral threats and pandemic preparedness. The Orphan Drug Designation adds a layer of commercial protection, potentially making NV-387 a valuable asset in the antiviral market.
More details about the offering can be found in the full press release at https://ibn.fm/Z8Etj. For the latest news and updates on NanoViricides, visit the company's newsroom at https://ibn.fm/NNVC.
